Lexeo Therapeutics (LXEO) Amortization - Intangibles (2025 - 2026)
Lexeo Therapeutics recorded quarterly Amortization - Intangibles of $42000.0 in Q1 2026, up 119.35% quarter-over-quarter from -$217000.0 in Q4 2025, and up 450.0% year-over-year from $7636.4 in Q1 2025.
Lexeo Therapeutics' Amortization - Intangibles history runs 2 years deep, the most recent figure standing at $42000.0 for Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 450.0% year-over-year to $42000.0; the TTM figure through Mar 2026 stood at -$81000.0 (changed N/A YoY), while the FY2025 annual figure was -$111000.0, down 582.61% from the prior year.
- Amortization - Intangibles came in at $42000.0 for Q1 2026 at Lexeo Therapeutics, up from -$217000.0 in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $60000.0 in Q3 2025 to a low of -$217000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | -217,000.00 |
| Sep 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | -12,000.00 |